| Autor: |
Amy Kwan, Faith Howard, Natalie Winder, Emer Atkinson, Ameera Jailani, Priya B. Patel, Richard Allen, Penelope D. Ottewell, Gary C. Shaw, Joe Conner, Caroline Wilson, Sanjay K. Srivastava, Sarah J. Danson, Claire Lewis, Janet E. Brown, Munitta Muthana |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Future Pharmacology, Vol 2, Iss 4, Pp 444-459 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2673-9879 |
| DOI: |
10.3390/futurepharmacol2040029 |
| Popis: |
Oncolytic viruses (OV) promote anti-tumour responses through the initiation of immunogenic cancer cell death which activates the host’s systemic anti-tumour immunity. We have previously shown that intravenously administered HSV1716 is an effective treatment for mammary cancer. However, intravenous administration of a virus has the potential to result in neutralization and sequestration of the virus which may reduce efficacy. Here, we show that the oncolytic virus HSV1716 can be administered within a cellular carrier (macrophages). PyMT and 4T1 murine mammary cancer cell lines were implanted into immuno-competent murine models (orthotopic primary, early metastatic and brain metastasis models). HSV1716 or macrophages armed with HSV1716 (M-HSV1716) were administered intravenously, and tumour size was quantified using caliper measurement or bioluminescence imaging. Administration of M-HSV1716 led to tumour shrinkage and increased the survival of animals. Furthermore, these results were achieved with a 100-fold lower viral load, which has the potential for decreased toxicity. Our results demonstrate that M-HSV1716 is associated with activity against murine mammary cancers and provides an alternative platform for the systemic delivery of OV. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
